Survie globale avec Osimertinib dans le NSCLC muté EGFR réséqué

Tsuboi et al. (Sun,) ont étudié cette question.

www.synapsesocial.com/papers/6941cf2d6ff23261fafbb7c7 — DOI: https://doi.org/10.1056/nejmoa2304594

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial· 2023 · 380 citations
2. Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial· 2022 · 25 citations
3. Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data· 2013 · 245 citations
4. 91P Treatment (tx) patterns and outcomes in resectable early-stage non-small cell lung cancer (NSCLC): A global real-world (rw) study· 2023 · 1 citations
5. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer· 2016 · 4,602 citations